IL231234A - Aromatase inhibitor for the treatment of hypogonadism and related diseases - Google Patents

Aromatase inhibitor for the treatment of hypogonadism and related diseases

Info

Publication number
IL231234A
IL231234A IL231234A IL23123414A IL231234A IL 231234 A IL231234 A IL 231234A IL 231234 A IL231234 A IL 231234A IL 23123414 A IL23123414 A IL 23123414A IL 231234 A IL231234 A IL 231234A
Authority
IL
Israel
Prior art keywords
hypogonadism
treatment
related diseases
aromatase inhibitor
aromatase
Prior art date
Application number
IL231234A
Other languages
English (en)
Hebrew (he)
Other versions
IL231234A0 (en
Original Assignee
Mereo Biopharma 2 Limited
Novartis Ag
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL231234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mereo Biopharma 2 Limited, Novartis Ag, Novartis Pharma Ag filed Critical Mereo Biopharma 2 Limited
Publication of IL231234A0 publication Critical patent/IL231234A0/en
Publication of IL231234A publication Critical patent/IL231234A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL231234A 2011-09-08 2014-02-27 Aromatase inhibitor for the treatment of hypogonadism and related diseases IL231234A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053844 WO2013036562A1 (en) 2011-09-08 2012-09-06 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Publications (2)

Publication Number Publication Date
IL231234A0 IL231234A0 (en) 2014-04-30
IL231234A true IL231234A (en) 2016-12-29

Family

ID=46846026

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231234A IL231234A (en) 2011-09-08 2014-02-27 Aromatase inhibitor for the treatment of hypogonadism and related diseases

Country Status (31)

Country Link
US (4) US9295668B2 (enExample)
EP (2) EP2753313B1 (enExample)
JP (2) JP6051467B2 (enExample)
KR (3) KR20140071358A (enExample)
CN (2) CN103796644B (enExample)
AR (1) AR087790A1 (enExample)
AU (2) AU2012304694B2 (enExample)
BR (2) BR112014005434B1 (enExample)
CA (2) CA2846884C (enExample)
CL (1) CL2014000552A1 (enExample)
CY (2) CY1118461T1 (enExample)
DK (2) DK2753312T3 (enExample)
ES (2) ES2613667T3 (enExample)
HR (2) HRP20170003T1 (enExample)
HU (2) HUE031478T2 (enExample)
IL (1) IL231234A (enExample)
IN (1) IN2014DN01619A (enExample)
LT (2) LT2753312T (enExample)
MX (2) MX343902B (enExample)
PE (1) PE20141584A1 (enExample)
PH (1) PH12014500435A1 (enExample)
PL (2) PL2753313T3 (enExample)
PT (2) PT2753313T (enExample)
RU (2) RU2617510C2 (enExample)
SG (2) SG2014012132A (enExample)
SI (2) SI2753312T1 (enExample)
TN (1) TN2014000059A1 (enExample)
TW (1) TW201316987A (enExample)
UY (1) UY34315A (enExample)
WO (2) WO2013036562A1 (enExample)
ZA (1) ZA201401040B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
PT3166596T (pt) * 2014-07-07 2018-10-19 Novartis Ag Formas farmacêuticas
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ,インコーポレーテッド 5−クロロ−n4−[2−(ジメチルホスホリル)フェニル]−n2−{2−メトキシ−4−[4−(4−メチルピペラジン−1−イル)ピペリジン−1−イル]フェニル}ピリミジン−2,4−ジアミンを含む医薬製剤
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤
US12552754B1 (en) 2025-06-11 2026-02-17 ReproNovo SA Leflutrozole compositions of matter and processes for preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (enExample) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU2001271162A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
SK14252003A3 (sk) 2001-04-17 2004-03-02 Ares Trading S. A. Použitie aromatázového inhibítora, farmaceutický prostriedok s obsahom aromatázového inhibítora a farmaceutické balenie
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
AU2003213957A1 (en) 2002-04-03 2003-10-13 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2006114702A2 (en) 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335219A (zh) * 2007-11-21 2012-02-01 客乐谐制药株式会社 芳香酶抑制剂
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni

Also Published As

Publication number Publication date
JP6280501B2 (ja) 2018-02-14
US20140213622A1 (en) 2014-07-31
PT2753312T (pt) 2017-02-03
US20140309267A1 (en) 2014-10-16
DK2753313T3 (en) 2017-02-13
AU2012304694A1 (en) 2014-03-20
HRP20170003T1 (hr) 2017-03-10
US9295668B2 (en) 2016-03-29
LT2753312T (lt) 2017-01-25
CY1118461T1 (el) 2017-07-12
ZA201401040B (en) 2015-12-23
CL2014000552A1 (es) 2014-09-12
CA2846884C (en) 2019-04-09
CA2845929A1 (en) 2013-03-14
SG2014012132A (en) 2014-06-27
BR112014004879A2 (pt) 2017-03-14
TW201316987A (zh) 2013-05-01
JP2014526465A (ja) 2014-10-06
RU2014113334A (ru) 2015-10-20
PH12014500435A1 (en) 2019-03-22
RU2014113575A (ru) 2015-10-20
EP2753312A1 (en) 2014-07-16
DK2753312T3 (da) 2017-02-13
CN103796644A (zh) 2014-05-14
CN103796644B (zh) 2017-05-03
US9370505B2 (en) 2016-06-21
CY1118499T1 (el) 2017-07-12
WO2013036562A1 (en) 2013-03-14
IL231234A0 (en) 2014-04-30
WO2013036563A1 (en) 2013-03-14
AU2012304694B2 (en) 2016-04-07
SG10201607503WA (en) 2016-10-28
AU2012304693A1 (en) 2014-03-13
BR112014005434B1 (pt) 2021-01-05
US20160346257A1 (en) 2016-12-01
KR101872561B1 (ko) 2018-06-28
PT2753313T (pt) 2017-02-02
CN103781476A (zh) 2014-05-07
RU2628808C2 (ru) 2017-08-22
CA2845929C (en) 2018-06-19
LT2753313T (lt) 2017-02-10
SI2753312T1 (sl) 2017-10-30
IN2014DN01619A (enExample) 2015-05-15
US10064844B2 (en) 2018-09-04
JP6051467B2 (ja) 2016-12-27
PL2753313T3 (pl) 2017-07-31
HRP20170002T1 (hr) 2017-02-24
EP2753312B1 (en) 2016-12-14
MX360315B (es) 2018-10-29
KR20140071358A (ko) 2014-06-11
AR087790A1 (es) 2014-04-16
US9750724B2 (en) 2017-09-05
ES2613667T3 (es) 2017-05-25
HUE031478T2 (hu) 2017-07-28
ES2613666T3 (es) 2017-05-25
JP2014528932A (ja) 2014-10-30
MX2014002773A (es) 2014-06-05
CA2846884A1 (en) 2013-03-14
BR112014005434A2 (pt) 2017-04-04
MX343902B (es) 2016-11-28
RU2617510C2 (ru) 2017-04-25
KR20140058619A (ko) 2014-05-14
MX2014002780A (es) 2014-06-05
NZ621476A (en) 2016-02-26
PE20141584A1 (es) 2014-11-13
HUE031435T2 (en) 2017-07-28
BR112014004879B1 (pt) 2020-01-28
US20160243084A1 (en) 2016-08-25
EP2753313B1 (en) 2016-12-14
EP2753313A1 (en) 2014-07-16
CN103781476B (zh) 2016-12-07
UY34315A (es) 2013-04-30
TN2014000059A1 (en) 2015-07-01
SI2753313T1 (sl) 2017-04-26
AU2012304693B2 (en) 2016-03-31
KR20180030254A (ko) 2018-03-21
PL2753312T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
LT2523661T (lt) Nkcc inhibitoriai autizmo gydymui
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
IL232421A0 (en) A dual inhibitor of met and vegf for cancer treatment
IL231234A0 (en) Use of an aromatase inhibitor to treat hypogonadism and related diseases
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201301601B (en) Treatment of diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
PT2772486T (pt) Inibidor de quinase e método para tratamento de doenças relacionadas
IL227972A0 (en) Use of glycopyrrolate to treat tachycardia
ZA201209323B (en) Methods of treating or preventing estrogen-related diseases
EP2707007A4 (en) FUNGICIDAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS
PL2900230T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2814317A4 (en) FUNGICIDAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS
SI2731616T1 (sl) Postopek preventive in zdravljenja sepse
ZA201403494B (en) Medicine for treatment and/or improvement of sepsis
ZA201208389B (en) Treatment of proliferative diseases
IL238592A0 (en) Methods for treating liver diseases
EP2934501A4 (en) USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201400956B (en) Treatment of sulphidic materials

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed